Evaluation of Primary Chronic Autonomic Failure
NCT00059033 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 325
Last updated 2019-12-12
Summary
This study will conduct tests in patients with primary chronic autonomic failure (CAF) to learn more about these disorders, which include pure autonomic failure, multiple system atrophy, Parkinson's disease with autonomic failure, and autoimmune autonomic neuropathy.
Healthy volunteers and patients with primary CAF 18 years of age or older may be eligible for this study. Participants undergo some of the following tests:
* Blood studies, including arterial catheter insertion to measure blood pressure and collect arterial blood samples, blood flow studies using sensors applied to the skin and a pressure cuff around a limb, and blood draw for genetic studies.
* Bladder motility: Ultrasound test of bladder function.
* Electrocardiogram and heart ultrasound.
* Responses to changes in temperature: Warm water and then room temperature water are passed through watertight pads applied to the back and front of the body and body temperatures are measured.
* Gastrointestinal motility: Bowel sounds are recorded using a microphone placed on the abdomen.
* Lower body negative pressure: The lower body is placed into an airtight barrel-like chamber. Some air is sucked out of the barrel, causing blood to pool in the legs, as occurs during standing.
* Lumbar puncture: A needle is inserted in the space between the bones in the lower back to collect a small sample of cerebrospinal fluid.
* Microdialysis to measures levels of chemicals in the body fluid of certain tissues. A solution is passed through a thin tube inserted into the skin. Chemicals in the body tissues enter the solution. The solution is collected and the chemical levels are measured.
* PET scanning: A nuclear medicine test to produce images of body organs. For patients with urinary problems, a catheter is inserted into the bladder before starting the scan.
* Pupillometry: The pupil of the eye is measured using a special camera in a light-controlled room.
* QSART. A small amount of a brain chemical is applied to the skin with a tiny amount of electricity, and the sweat in a nearby patch of skin is measured.
* Measurement of saliva production, using a cotton-like material placed between the teeth and gums to absorb saliva.
* Skin electrical conduction test, using sensors on the skin to measure sweat production.
* Skin and core temperature measurements using sensors on the skin and in the ear canal.
* Speech and swallowing assessment for patients with speech and swallowing difficulties.
* Stress echocardiogram: A catheter is placed in the subject's arm for sampling blood or giving a drug while the subject exercises. During the test, blood pressure, pulse rate, and EKG are continuously monitored.
Conditions
- Autonomic Nervous System Diseases
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Principal Investigators
-
David S Goldstein, M.D. · National Institute of Neurological Disorders and Stroke (NINDS)
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-04-10
- Completion
- 2018-10-30
Countries
- United States
Study Locations
More Related Trials
-
Nilotinib in Parkinson's Disease
NCT03205488 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine
NCT02365012 ·Status: UNKNOWN ·Phase: NA
-
Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease
NCT07118956 ·Status: RECRUITING ·Phase: NA
-
Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy
NCT00005903 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
NCT00006077 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease
NCT00558337 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
NCT02352363 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
NCT03295786 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease
NCT03119636 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease
NCT02683629 ·Status: COMPLETED ·Phase: PHASE2
-
Infusion of Apomorphine: Long-term Safety Study
NCT02339064 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
NCT05487300 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of LY300164 for the Treatment of Parkinson's Disease
NCT00004576 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease
NCT01453803 ·Status: WITHDRAWN ·Phase: NA
-
ACP-103 to Treat Parkinson's Disease
NCT00086294 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449 ·Status: RECRUITING ·Phase: PHASE1
-
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
NCT01617135 ·Status: COMPLETED ·Phase: PHASE2
-
Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson
NCT05699161 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)
NCT05377281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
NCT02240030 ·Status: COMPLETED ·Phase: PHASE3
-
Fipamezole in Neurogenic Orthostatic Hypotension
NCT00758849 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
NCT00633880 ·Status: COMPLETED ·Phase: PHASE3
-
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
NCT02242487 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
NCT04514367 ·Status: COMPLETED ·Phase: PHASE2
-
Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease
NCT05691114 ·Status: RECRUITING ·Phase: PHASE1